Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue
Neuritin 1, secreted by brown adipose tissue, enhances thermogenic activity and reduces fat mass. Its upregulation under RAP250 deficiency highlights its potential as a novel therapeutic target for obesity and related metabolic disorders.
VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome (ICOMES)
September 4, 2025 / QSYMIA / Obesity management / Phentermine topiramate / QUEEN’s study / Metabolic health
At ICOMES 2025, VIVUS highlighted QSYMIA®’s sustained efficacy in obesity management, supported by the QUEEN’s study showing significant weight loss and metabolic improvements in Korean adults using phentermine/topiramate alongside lifestyle interventions.
224 health risks lurk behind obesity: Doctor explains the science you can’t afford to ignore
Novonesis and Novo Nordisk collaborate to advance metabolic health solutions
September 8, 2025 / Gut microbiome / Metabolic health / Synbiotic supplements / Obesity prevention / Novo Nordisk partnership
Novo Nordisk and Novonesis are collaborating to develop synbiotic solutions targeting gut microbiome health, aiming to prevent and manage obesity and related metabolic disorders by improving glucose, cholesterol, and identifying novel biomarkers for personalized metabolic health interventions.
Activating brown fat may yield a new strategy to tackle obesity
September 4, 2024 / Neuritin 1 / Brown fat activation / Obesity treatment / Energy expenditure / Metabolic health
A single fecal transplant provides years of health benefits
A single oral fecal microbiota transplant in obese teens produced long-term metabolic benefits—reducing waist size, body fat, inflammation, and heart disease risk—lasting over four years, highlighting the microbiome’s therapeutic potential in preventing metabolic syndrome.
How social challenges shape gut health and drive obesity risk
September 4, 2025 / Gut-brain axis / Social determinants / Obesity risk / Microbiome disruption / Chronic stress
UCLA researchers highlight how social determinants—like stress, discrimination, and low socioeconomic status—alter the gut-brain axis, increasing obesity risk by disrupting gut microbiota, appetite regulation, and metabolic function, emphasizing the need for systemic and personalized interventions.
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health
September 8, 2025 / Gut microbiome / Metabolic health / Synbiotic supplements / Chronic disease prevention / Novo Nordisk partnership
Novo Nordisk and Novonesis are partnering to develop synbiotic solutions targeting the gut microbiome, aiming to improve metabolic health by regulating glucose and cholesterol, identifying predictive biomarkers, and preventing chronic diseases like obesity, type 2 diabetes, and cardiovascular disease.
Morphic Medical has positive results for endoscopic device targeting diabetes, obesity
September 8, 2025 / Endoscopic device / Obesity treatment / Type 2 diabetes / Gut hormone therapy / Morphic Reset
Morphic Medical’s incision-free Reset device offers significant, durable weight loss and blood sugar improvement in obesity and type 2 diabetes, mimicking gut hormone effects like GLP-1s. Real-world data shows benefits lasting up to three years post-removal.
ATTAIN-2 Trial Shows Lilly’s Orforglipron Achieves Weight and A1C Reductions Consistent With Injectable GLP-1s
September 2, 2024 / Orforglipron / Oral GLP-1 / Weight loss / Type 2 diabetes / Cardiometabolic health
Lilly’s oral GLP-1 agonist, orforglipron, achieved significant weight loss and A1C reduction in the ATTAIN-2 trial, matching injectable GLP-1 therapies. It also improved cardiometabolic markers, with a tolerable safety profile, supporting global regulatory submissions for obesity and type 2 diabetes.
New study links grain foods to healthier diet patterns, metabolic health and everyday accessibility
September 4, 2025 / Healthy grain foods / Nutrient density / Metabolic health / Refined grains / Diet quality
Low-Carb Diet Offers Benefits for People with Fatty Liver Disease
September 8, 2025 / Low-carb diet / Fatty liver disease / MASLD treatment / Metabolic health / Cardiometabolic risk
Low-carbohydrate diets significantly improve weight, blood sugar, triglycerides, and insulin resistance in people with MASLD, offering a promising lifestyle intervention for managing fatty liver disease and reducing cardiometabolic risk, even over short durations.
Biomed Industries to Present Pivotal Studies at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
September 2, 2025 / NA 931 / Obesity treatment / MASH therapy / Quadruple agonist / Liver disease
Biomed Industries’ NA 931, a novel quadruple receptor agonist, showed up to 13.8% weight loss in Phase 2 trials for obesity and MASH, with preserved muscle mass and minimal GI side effects, highlighting promise for cardiometabolic disease treatment.
Nottingham research partnership to tackle obesity and drive UK-wide innovation
September 2, 2025 / Obesity research / Early career scientists / Metabolic health / UK bioscience / NOBLE network
The NOBLE network, launched by Nottingham universities with UKRI support, empowers early career researchers in obesity and metabolism through funding, training, and collaboration—aiming to drive UK-wide innovation and improve long-term health outcomes in obesity and metabolic disease.
Barcelona scientists identify protein to reduce obesity, challenging Ozempic
September 4, 2025 / Neuritin 1 / Brown fat / Obesity treatment / Energy expenditure / Metabolic health
Barcelona scientists identified Neuritin 1, a protein in brown fat that boosts energy expenditure without reducing food intake, improving insulin sensitivity and liver inflammation—offering a novel therapeutic pathway for obesity, distinct from appetite-suppressing drugs like Ozempic.
Nitric Oxide Knockdown Affects GABA Neuron Metabolism in Rats
September 7, 2025 / Nitric oxide / GABA neurons / Energy regulation / Hypothalamus function / Metabolic signaling
Knocking down nitric oxide synthase in the ventromedial hypothalamus alters GABAergic gene expression in rats, revealing nitric oxide’s key role in regulating inhibitory neural circuits tied to energy balance, appetite, and metabolic function.
High demand for weight loss drugs led to shortage for type 2 diabetes patients: Lancet
September 8, 2025 / Semaglutide shortage / Type 2 diabetes / GLP-1 drugs / Obesity treatment / Global health equity
Surging demand for semaglutide for weight loss has caused global shortages, limiting access for type 2 diabetes patients who depend on it for glycemic control. The Lancet highlights urgent concerns over affordability, equity, and access in low- and middle-income countries.
Study Finds Overeating, Not Inactivity, Drives Obesity in Wealthier Societies
September 6, 2025 / Obesity drivers / Calorie intake / Diet vs exercise / Ultra-processed foods / Metabolic health
A global study confirms excess calorie intake—not reduced physical activity—is the main driver of obesity in industrialized societies, highlighting the need for diet-focused interventions targeting ultra-processed foods to effectively combat rising obesity and related chronic diseases.
Molecule shows promise for MASH, endometriosis and other chronic diseases
September 4, 2025 / Bobcat339 molecule / TET3 inhibition / Chronic inflammation / MASH treatment / Macrophage targeting
Researchers identified a molecule, Bobcat339, that selectively targets pathogenic macrophages by degrading TET3, reducing inflammation in MASH, endometriosis, and NSCLC without harming healthy cells—offering a promising, disease-specific therapeutic approach for multiple chronic inflammatory conditions.
Association of Metabolic Syndrome and Stroke in Adults: A Case-Control Study
September 4, 2025 / Metabolic syndrome / Stroke risk / India study / Modifiable factors / Non-communicable diseases
This Indian case-control study confirms metabolic syndrome significantly increases stroke risk, along with modifiable factors like high salt intake, elevated BMI, and tobacco use—highlighting the urgent need for targeted NCD screening and early intervention strategies in at-risk populations.